Cutaneous Melioidosis in Adolescent Returning from Guadeloupe by Meckenstock, Roderich et al.
LETTERS
  6. Brown IH. The epidemiology and evolution 
of inﬂ  uenza viruses in pigs. Vet Microbiol. 
2000;74:29–46. http://dx.doi.org/10.1016/
S0378-1135(00)00164-4
  7.   Ma W, Gramer M, Rossow K, Yoon KJ. 
Isolation and genetic characterization 
of new reassortant H3N1 swine inﬂ  u-
enza virus from pigs in the midwestern 
United States. J Virol. 2006;80:5092–6. 
http://dx.doi.org/10.1128/JVI.80.10.5092-
5096.2006
  8.   Vijaykrishna D, Poon LL, Zhu HC, Ma SK, 
Li OT, Cheung CL, et al. Reassortment of 
pandemic H1N1/2009 inﬂ  uenza A  virus 
in swine. Science. 2010;328:1529. http://
dx.doi.org/10.1126/science.1189132
   9.   Chen H, Wang Y, Liu W, Zhang J, Dong B, 
Fan X, et al. Serologic survey of pandemic 
(H1N1) 2009 virus, Guangxi Province, 
China. Emerg Infect Dis. 2009;15:1849–
50.
Address for correspondence: Qi Liu, Guangxi 
Center for Animal Disease Control and 
Prevention, Nanning 530001, Guangxi, People’s 
Republic of China; email: lqzz888@sina.com
Cutaneous 
Melioidosis in 
Adolescent 
Returning from 
Guadeloupe
To the Editor: Melioidosis is an 
emerging zoonosis caused by a highly 
invasive and drug-resistant bacterium, 
Burkholderia pseudomallei, that 
is found in soil and is endemic to 
Southeast Asia and the Paciﬁ  c region. 
Few cases occur in other regions 
(most imported by travelers) (1–5), 
but sporadic cases have originated 
from the Caribbean (6–8).
Melioidosis can manifest 
many years after exposure to B. 
pseudomallei and can cause severe, 
systemic infection, including multiple 
abscesses of internal organs and skin. 
A less severe manifestation, primary 
cutaneous melioidosis, causes skin 
lesions and milder clinical illness. 
We describe an adolescent patient 
who had a benign, cutaneous form 
of melioidosis; she had recently 
returned to France from Guadeloupe, 
a Caribbean archipelago.
A 15-year-old girl without a 
medical history, except for asthma, 
was evaluated in September 2010 for 
muscle weakness, weight loss of 15%, 
cough, and fever >40°C. During a trip 
to Guadeloupe 3 weeks before, she 
had been infected by dengue virus, 
along with her brother and father, 
who recovered rapidly. Treatment 
with amoxicillin and clavulanic acid 
was started after her return to France, 
despite the lack of a clear diagnosis, 
and induced a slight decrease in fever. 
Clinical examination showed 
a body mass index <15, multiple 
small adenopathies (<10 mm), 
small papulous skin eruptions, 
and an inﬂ  ammatory  15-mm–wide 
tumefaction on the upper arm, 
evoking an adenopathy on ultrasound 
investigation. Biological screening 
2 weeks later showed persistence of 
inﬂ   ammation. Results of serologic 
tests for cytomegalovirus, Epstein-Barr 
virus, parvovirus B19, chikungunya 
virus, Rickettsia, Coxiella, Chlamydia, 
Brucella, and Borrelia spp. did not 
show acute infectious disease; results 
were positive for recent mycoplasma 
infection, despite absence of typical 
signs and symptoms. A 2-week 
treatment regimen with spiramycin 
was started; general improvement 
followed, and the cough resolved. 
The tumefaction of the upper arm 
persisted, and a biopsy was performed. 
Histologic results were nonspeciﬁ  c; 
culture on sheep’s blood Columbia 
agar and chocolate agar produced 
small colonies of gram-negative 
bacilli after 24 hours’ incubation at 
35°C in an atmosphere of 5% CO2. 
This bacillus was later identiﬁ  ed  as 
B. pseudomallei by using the Vitek2 
test card (bioMérieux, Marcy l’Etoile, 
France). Identiﬁ  cation was conﬁ  rmed 
by sequencing of 16S rRNA.
The patient was treated with 
intravenous ceftazidime (150 mg/kg 
for 10 d), followed by oral cotri-
moxazole (800 mg of trimethoprim 
and 160 mg of sulfamethoxazole, 
2×/d), with a total treatment duration 
of 12 weeks. Eleven weeks after 
treatment ended, the patient had 
recovered, and the tumefaction of the 
arm had disappeared.
The differential diagnosis for 
primary cutaneous melioidosis 
includes pyogenic abscesses, 
insect bites, mycobacterial and 
other granulomatous lesions, and 
adenopathies, but melioidosis is 
usually not suspected in these 
conditions, particularly in patients 
from non–disease-endemic regions 
such as the Caribbean. Clinical 
phenotypes of melioidosis range from 
asymptomatic carriage to fulminant 
shock syndrome (1–5); death rates 
for the latter are ≈100% (3). Subacute 
melioidosis may be associated with 
pulmonary and general signs; chronic 
variants could give rise to abscesses 
or septicemia in cases of concomitant 
immunodeﬁ  ciency  (1–5), even 
decades after exposure. Signs and 
symptoms of melioidosis can mimic 
those of tuberculosis, even though 
there is no link between the infectious 
agents (2,4).
Cutaneous melioidosis may 
be primary (a single, nonspeciﬁ  c, 
sometimes ulcerated lesion, 
measuring from several millimeters 
to several centimeters) or secondary 
(multiple lesions associated with 
visceral infection). In a study of 486 
melioidosis patients in Australia, 58 
(12%) had the primary cutaneous form 
(9). These cases were characterized by 
younger patient age (more common 
among children <16 years of age), 
higher frequency during the dry 
season, better prognosis in spite of 
a possible chronic evolution, and 
absence of classic risk factors (9) such 
as diabetes, alcoholism, chronic renal 
or pulmonary infections, surgery, 
pregnancy, or cystic ﬁ  brosis (1–5).
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The case we describe is consistent 
with the cutaneous variant of 
melioidosis. However, the patient’s 
initial general symptoms (probably 
attenuated by early treatment with 
antimicrobial drugs) could have 
indicated a transitory, disseminated 
phase of disease such as that 
experienced by 4 (all adults) of the 58 
cases of primary cutaneous melioidosis 
in the Australian study (9). It is not 
known whether B. pseudomallei 
was transmitted to the patient by an 
airborne route or percutaneously as 
in most cases (i.e., wounds infected 
by contaminated water or mud); other 
transmission modes are anecdotal 
(1–5). Moreover, our patient had none 
of the classic risk factors, although 
dengue fever as an underlying co-
infection has been described (10).
The patient was treated with 
intravenous ceftazidime and oral 
cotrimoxazole at the minimum 
treatment duration recommended for 
melioidosis (1–5). Purely cutaneous 
variants of melioidosis may be treated 
exclusively by oral cotrimoxazole 
over 12 weeks (9), but we opted 
to prescribe initial intravenous 
treatment because of her general 
symptoms. We stopped follow-up 
11 weeks after the treatment period 
ended because of persisting illness 
remission, but lifelong monitoring is 
recommended for adult patients (1,4) 
because relapses occur in ≈10% of 
adult patients despite well-conducted 
antimicrobial drug treatment (3,4).
In conclusion, melioidosis as a 
potential emerging infectious disease 
should be considered in cases of 
isolated skin lesions as well as in cases 
of unexplained fever with nonspeciﬁ  c 
symptoms. Furthermore, the disease 
should be considered not only among 
travelers returning from known 
disease-endemic regions but also in 
those coming from the Caribbean. 
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Geographic 
Distribution of 
Endemic Fungal 
Infections among 
Older Persons, 
United States
To the Editor: We read with 
interest the article by Baddley 
et al. (1) and appreciate their 
efforts to characterize incidence 
rates of mycoses. We agree that 
histoplasmosis, blastomycosis, and 
coccidioidomycosis are differential 
diagnoses for patients with consistent 
symptoms but who reside outside 
mycosis-endemic areas.
However, we believe that the 
methods of Baddley et al. probably 
do not determine the true incidence of 
these mycoses in sparsely populated 
states such as Arkansas. Their estimates 
contrast markedly with surveillance 
data from the Arkansas Department 
of Health (Table) and with our clinical 
experience as infectious disease 
physicians. We characterize Arkansas 
as a state in which histoplasmosis and 
blastomycosis incidence is high and 
coccidioidomycosis incidence is low; 
however, Baddley et al. indicate that in 
Arkansas, incidence of blastomycosis 
is relatively low and incidence of 
coccidioidomycosis is high.
To investigate whether this 
ﬁ   nding might be associated with 
their small 5% sample of Medicare 
beneﬁ  ciaries, we used data from the 
Arkansas census to determine that 
in 2008 the population of adults 
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